Navigation Links
Treatment target identified for a public health risk parasite

This news release is available in French.

Montreal, November 26, 2013 In the developing world, Cryptosporidium parvum has long been the scourge of freshwater. A decade ago, it announced its presence in the United States, infecting over 400,000 people the largest waterborne-disease outbreak in the county's history. Its rapid ability to spread, combined with an incredible resilience to water decontamination techniques, such as chlorination, led the National Institutes of Health (NIH) in the United Sates to add C. parvum to its list of public bioterrorism agents. Currently, there are no reliable treatments for cryptosporidiosis, the disease caused by C. parvum, but that may be about to change with the identification of a target molecule by investigators at the Research Institute of the McGill University Health Centre (RI-MUHC). The findings of this study have been recently published in the Antimicrobial Agents and Chemotherapy (AAC) journal.

"In the young, the elderly and immunocompromised people such as people infected with HIV/Aids, C. parvum is a very dangerous pathogen. Cryptosporidiosis is potentially life-threatening and can result in diarrhea, malnutrition, dehydration and weight loss," says first author of the study, Dr. Momar Ndao, Director of the National Reference Centre of Parasitology (NRCP) at the MUHC and an Assistant Professor of the Departments of Medicine, Immunology and Parasitology (Division of Infectious Diseases) at McGill University.

The oocysts of C. parvum, which are shed during the infectious stage, are protected from a thick wall that allows them to survive for long periods outside the body as they spread to a new host. C. parvum is a microscopic parasite that lives in the intestinal tract of humans and many other mammals. It is transmitted through the fecal-oral contact with an infected person or animal, or from the ingestion of contaminated water or food. Since the parasite is resistant to chlorine and difficult to filter, cryptosporidiosis epidemics are hard to prevent.

"Most protozoan (single-celled) parasites like C. parvum use enzymes called proteases to escape the body's immune defenses," explained Dr. Ndao, who is also a researcher in the Infection and Immunity Axis of the RI-MUHC. "In this study, we were able to identify a protease inhibitor that can block the parasite's ability to circumvent the immune system, and hide in intestinal cells called enterocytes, in order to multiply and destroy the intestinal flora."

The discovery, which was made in collaboration with US researchers, is the first time a molecular target has been found for the control of C. parvum. "The next step will be to conduct human clinical trials to develop an effective treatment for this parasite, which affects millions of people around the world," concludes Dr. Ndao.


Contact: Julie Robert
514-934-1934 x71381
McGill University Health Centre

Related biology news :

1. Breakthroughs in Chikungunya research from A*STAR spell new hope for better treatment and protection
2. Collaborative preclinical efficacy studies suggest a new target for drug addiction treatment
3. Genetic research develops tools for studying diseases, improving regenerative treatment
4. Step forward in research into new treatments for brain edema
5. Marshall University study may lead to new treatments for prostate cancer
6. New discoveries about brain-hand connection sought to improve therapies, treatments, prosthetics
7. Minimally invasive treatment for ruptured aneurysm: Safe, reduces mortality
8. Penn research points to new way of preserving fertility for boys undergoing cancer treatment
9. Researcher who identifed genetic cause and possible treatment for Marfan syndrome honored
10. New discovery may lead to effective prevention and treatment of graft-versus-host dsease
11. Antipsychotic drug may be helpful treatment for anorexia nervosa
Post Your Comments:
Related Image:
Treatment target identified for a public health risk parasite
(Date:4/15/2016)... -- Research and Markets has announced the ...  report to their offering.  ,      ... gait biometrics market is expected to grow at ... Gait analysis generates multiple variables such ... compute factors that are not or cannot be ...
(Date:4/13/2016)... physicians supporting Medicaid patients in Central Florida ... telehealth thanks to a new partnership with higi.   ... can routinely track key health measurements, such as blood ... they opt in, share them with IMPOWER clinicians through ... location at no cost. By leveraging this data, IMPOWER ...
(Date:3/31/2016)...  Genomics firm Nabsys has completed a financial  restructuring ... , M.D., who returned to the company in October ... team, including Chief Technology Officer, John Oliver , ... and Vice President of Software and Informatics, Michael ... Dr. Bready served as CEO of Nabsys from 2005-2014 ...
Breaking Biology News(10 mins):
(Date:6/23/2016)... - FACIT has announced the creation of a ... Propellon Therapeutics Inc. ("Propellon" or "the Company"), to ... of first-in-class WDR5 inhibitors for the treatment of ... an exciting class of therapies, possessing the potential ... patients. Substantial advances have been achieved with the ...
(Date:6/23/2016)... June 23, 2016  The Prostate Cancer Foundation (PCF) is pleased ... and faster cures for prostate cancer. Members of the Class of 2016 were ... Read More About the Class of 2016 PCF Young ... ... ...
(Date:6/23/2016)... ... June 23, 2016 , ... STACS DNA Inc., the sample tracking software company, ... Crime Laboratory, has joined STACS DNA as a Field Application Specialist. , “I ... President and COO of STACS DNA. “In further expanding our capacity as a scientific ...
(Date:6/23/2016)... LONDON , June 23, 2016 ... & Hematology Review, 2016;12(1):22-8 ... Review , the peer-reviewed journal from touchONCOLOGY, ... the escalating cost of cancer care is placing ... a result of expensive biologic therapies. With the ...
Breaking Biology Technology: